Hamburg, Germany | Oxfordshire, UK - Evotec OAI AG (Deutsche Börse: EVT, TecDAX 30), a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries, today announced that it has entered into an integrated virtual screening and medicinal chemistry collaboration with Fujisawa Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer in Japan, to identify, synthesise and optimise compounds that show biological activity against one of Fujisawa's drug targets.
A dedicated team of Evotec OAI chemists will work on this project in close collaboration with Fujisawa. Using integrated virtual screening and compound design software/expertise Evotec OAI will mine their chemical databases to identify and synthesise compounds that are predicted to be active against the target. Fujisawa will conduct biological screening of the compounds. In parallel, using Evotec OAI's state-of-the-art medicinal chemistry platform, these hits will be further optimised in terms of their potency, selectivity, in vitro ADMET and pharmacokinetic profile for the subsequent progression into a lead optimisation programme.
Evotec OAI will receive fees for services carried out and milestone payments for the successful achievement of predefined scientific results. Financial terms and Fujisawa's drug target were not disclosed.
Bernard Questier, Chief Business Officer of Evotec OAI, said: "We are extremely pleased and honoured to enter into this major collaboration with Fujisawa, a leading Japanese pharmaceutical company. This agreement demonstrates once again that our engagement and flexibility in integrating our technology platform supplements the drug discovery projects performed by companies in Japan, a market of significant importance to Evotec OAI."
About Evotec OAI AG
Evotec OAI has established itself as the partner of choice for drug discovery and development solutions for pharmaceutical and biotechnology companies worldwide, maintaining its leadership role through innovation and unmatched customer service.
The Company's business strategy is clearly focussed on drug discovery. It has established the most comprehensive technology platform and skills that integrate its world-class biology and chemistry capabilities. Evotec OAI leverages this discovery engine in providing assay development and screening through to compound optimisation and drug manufacturing services to a broad and well-established network of customers. In addition, the Company engages in selected discovery programmes itself to develop drug candidates for early out-licensing. Evotec OAI's instrument and technology business is now successfully handled by its affiliate, Evotec Technologies.
With over 600 people in Hamburg, Germany and Oxfordshire, UK, Evotec OAI is dedicated to returning value to its shareholders and employees through a sustainable business strategy that balances short-term and long-term revenue opportunities.
www.evotecoai.com
About Fujisawa Pharmaceutical Co., Ltd.
Founded in 1894, Fujisawa Pharmaceutical Co., Ltd. looks back on a history of over 100 years that have seen the Company develop into one of the leading pharmaceutical manufacturers in Japan. The Company forms the core of the Fujisawa Group, which as a result of global business expansion now has offices, plants and research facilities in Japan, North America, Europe and Asia with more than 8,000 employees worldwide.
As a research-driven pharmaceutical company, Fujisawa's research and development activities are the key to its success in the highly competitive global market. Under the banner of "speed, focus and persistence," Fujisawa is deeply committed to innovative research to satisfy unmet medical needs. Fujisawa is also keen on strengthening its strategic collaboration with outside institutions or emerging research ventures that possess novel technology or ideas for drug discovery.
www.fujisawa.co.jp
Contact Evotec OAI AG:
Anne Hennecke
Investor Relations & Corporate Communications
+49-40-56081-286
+49-40-56081-333
anne.hennecke@evotecoai.com
Contact Evotec OAI AG:
Anne Hennecke
Investor Relations & Corporate Communications
+49-40-56081-286
+49-40-56081-333
anne.hennecke@evotecoai.com
Evotec OAI Enters into Integrated Virtual Screening and Medicinal Chemistry Agreement with Fujisawa
TOP